2,387 reports of this reaction
2.2% of all METFORMIN HYDROCHLORIDE TABLET reports
#7 most reported adverse reaction
DYSPNOEA is the #7 most commonly reported adverse reaction for METFORMIN HYDROCHLORIDE TABLET, manufactured by EPIC PHARMA, LLC. There are 2,387 FDA adverse event reports linking METFORMIN HYDROCHLORIDE TABLET to DYSPNOEA. This represents approximately 2.2% of all 107,050 adverse event reports for this drug.
Patients taking METFORMIN HYDROCHLORIDE TABLET who experience dyspnoea should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
DYSPNOEA is a less commonly reported adverse event for METFORMIN HYDROCHLORIDE TABLET, but still significant enough to appear in the safety profile.
In addition to dyspnoea, the following adverse reactions have been reported for METFORMIN HYDROCHLORIDE TABLET:
The following drugs have also been linked to dyspnoea in FDA adverse event reports:
DYSPNOEA has been reported as an adverse event in 2,387 FDA reports for METFORMIN HYDROCHLORIDE TABLET. This does not prove causation, but indicates an association observed in post-market surveillance data.
DYSPNOEA accounts for approximately 2.2% of all adverse event reports for METFORMIN HYDROCHLORIDE TABLET, making it a notable side effect.
If you experience dyspnoea while taking METFORMIN HYDROCHLORIDE TABLET, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.